Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study).
EU CTIS ID: 2024-519770-38-00
What this study is testing
- Temporal Evolution of Biochemical Marker Levels in Blood During NTG-Induced Migraine Attacks and After Treatment with Sumatriptan and Rimegepant - Correlation of Biochemical Marker Profiles with Acute Treatment Response to Sumatriptan and Rimegepant During NTG-Induced Migraine Attacks.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults between 18 and 60 years old.
- Diagnosis of migraine, with or without aura, according to the The International Classification of Headache Disorders 3rd edition.
- According to the calendar, frequency of cefalea < 10 days/month.
- Signature of the Inform Consent Form.
You likely can't join if
- Contraindication to nitroglycerin
- Child-bearing women that not use one acceptable method of birth contro
- History of poor tolerance or prior hypersensitivity reaction to triptans or gepants
- History of severe or refractory migraine attacks unresponsive to treatment with triptans, gepants, or NSAIDs
- Preventive treatment for migraines (includes antidepressants, beta-blockers, lisinopril or candesartan, topiramate, valproic acid, botulinum toxin, or CGRP-targeted therapies).
- Tretament with drugs acting on the central nervous system
See the full eligibility criteria
- Adults between 18 and 60 years old.
- Diagnosis of migraine, with or without aura, according to the The International Classification of Headache Disorders 3rd edition.
- According to the calendar, frequency of cefalea < 10 days/month.
- Signature of the Inform Consent Form.
- Contraindication to nitroglycerin
- Child-bearing women that not use one acceptable method of birth contro
- History of poor tolerance or prior hypersensitivity reaction to triptans or gepants
- History of severe or refractory migraine attacks unresponsive to treatment with triptans, gepants, or NSAIDs
- Preventive treatment for migraines (includes antidepressants, beta-blockers, lisinopril or candesartan, topiramate, valproic acid, botulinum toxin, or CGRP-targeted therapies).
- Tretament with drugs acting on the central nervous system
- Relevant medical or psychiatric diseases
- History of unstable ischemic heart disease, cerebrovascular disease, peripheral vasculopathy
- History of significant hepatic disease
- Pregnant women
The study team makes the final eligibility decision.
Where it's taking place
- Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.